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Available online 16 March 2016Background:Mice are frequently used in research to examine outcomes of myocardial infarction (MI) and to in-
vestigate therapeutic interventions at an early pre-clinical stage. TheMImodel is generated by surgically occlud-
ing a major coronary artery, but natural variation in murine coronary anatomy can generate variable outcomes
that will inevitably affect the accuracy of such investigations. The aim of this study was to use MRI to derive
the most sensitive early variable that could be used to predict subsequent adverse cardiac remodelling in a
male mouse model of MI.
Methods:Using a longitudinal study design, heart structure and functionwere evaluated using cardiacMRI at one
week following surgical MI to generate the early measurements and again at four weeks, when the scar hadma-
tured. The primary variables measured at week onewere left ventricular volumes at end systole (LV-ESV) and at
end diastole (LV-EDV), infarct size, LV-cardiac mass, and ejection fraction (EF).
Results:Univariate andmultiple regression analyses showed that LV-ESV at oneweek followingMI could be used
to accurately predict various parameters of adverse LV remodelling at four weeks post-MI. However, the highest
correlation was between LV-ESV at one week following MI and LV-EDV at four weeks (r = 0.99; p b 0.0001),
making LV-ESV at one week a valuable predictor variable of future adverse ventricular remodelling after MI.
Conclusion: Using MRI to determine LV-ESV at an early stage following MI enables a more robust analysis of po-
tential therapeutic interventions to ameliorate adverse cardiac remodelling.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Myocardial infarction
Animal models of human disease
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MRI1. Introduction
It is well established that myocardial infarction resulting from the oc-
clusion of a major coronary artery leads to cardiomyocyte necrosis and
initiates a wound healing response. The resultant combination of cardio-
myocyte death, inflammation and fibrosis leads to a situationwhere non-
contractile scar tissue gradually replaces the infarcted myocardial tissue.
Furthermore, increased pressure/volume load on the non-ischaemic
myocardium leads to cardiac hypertrophy in non-infarcted areas, increas-
ing the functional impairment of the affected ventricle and contributing to
additional adverse remodelling. In parallel, systemic neurohormonal acti-
vation also contributes to progressive, adverse ventricular remodelling
and development of heart failure [1–3]. Many of these processes occurdicine, Newcastle University,
eliability and freedom from bias
am, HU16 5JQ, UK.
land Ltd. This is an open access articlin a similar manner in rodents and humans, and consequently mouse
models of MI have beenwidely used to understand the processes leading
to adverse ventricular remodelling and to investigate therapeutic inter-
ventions in the pre-clinical setting. Studies on mice also offer the advan-
tage of being able to target genes of interest using genetic tools (e.g.
Cre/Lox) to investigate gene-specific functions in heart injury and repair.
Surgical occlusion of a major left ventricular coronary artery in a
wild type mouse is frequently used to model myocardial infarction [4].
Usually the left anterior descending (LAD) artery is ligated, immediately
below the left auricle. This occludes the vascular supply to much of the
free wall of the left ventricle (LV), sparing the septum and most of the
right ventricle. However, even in experienced hands, the microsurgery
leads to variation in infarct size due to (i) natural variation in coronary
anatomy between individuals, and (ii) sub-millimetre differences in
the surgeon's placement of the suture over the LAD [5]. Therefore, im-
proved methods of predicting adverse cardiac remodelling are required
to evaluate therapeutic improvementwithin the context of this baseline
variation. This goal is of prime importance because reported effective
therapies in mouse models of myocardial infarction to date are rarely
translated to the clinic [6] and poor experimental design of mousee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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field urgently requires a study design that can incorporate natural vari-
ation in infarct size and can be used as a robust basis for investigating ef-
fective therapeutic interventions.
A range of studies have investigated baseline outcomes in mouse
models ofMI. For example, Shioura and colleagues showed that surgical
ligation of the left main coronary artery in wild type (C57BL/6) male
mice showed an initial drop in systolic function, followed by a transient
improvement before further decline in both systolic and diastolic func-
tion that correlated with dynamic changes in foetal gene expression,
characteristic of heart failure [7]. However, a major limitation of this
study, and other similar studies that use conductance catheters to
examine cardiac function, is that each analysis involves a terminal
procedure, prohibiting longitudinal studies. In contrast, cardiac MRI
provides a powerful technique to measure heart function under tran-
sient anaesthesia and is considered the “gold standard” permitting lon-
gitudinal studies to track cardiac function in individual animals [8].
Using this technique Protti and colleagues recently investigated adverse
cardiac remodelling following surgical ligation of the LAD in wild-type
(C57BL/6)mice [9]. They observed that left ventricular end diastolic vol-
ume (LV-EDV) at an early stage (2 days) followingMI was predictive of
the adverse cardiac remodelling outcome at 30 days and that infarcted
mice fell into two groups (i) progression and (ii) non-progression,
with non-progression associated with small infarct size. However,
their study was limited to female mice and a growing body of evidence
from animal studies suggests that females exhibit a different pattern of
post-MI healing and left ventricular remodelling compared to males. In
essence, there is less inflammation and increased reparative fibrosis
during infarct healing in femalemice leading to reduced LV remodelling
comparedwithmalemice [10–13]. Also, in a clinical context, MI ismore
common in men than women [14,15] so it is also important to deter-
mine robust predictive measures in male animal models. To address
this issue we investigated longitudinal outcomes using MRI in a male
mousemodel ofmyocardial infarction to determinewhich early adverse
events were best able to predict further progression of adverse remod-
elling and could be used tomeasure the benefit of therapeutic outcomes
in future studies.2. Methods
2.1. Mouse model of myocardial infarction
All in vivo procedures were conducted in accordance with the
Guidance on the Operation of the Animals (Scientific Procedures)
Act, 1986 (UK Home Office) and approved by the local ethics com-
mittee. Acute MI was created in 25 adult male C57BL/6 mice (12 to
14 weeks of age) using a procedure adapted from a published proto-
col [16]. Mice were pre-medicated with fentanyl/fluanisone
(‘Hypnorm’, 0.4 ml/kg) to provide intra-operative analgesia and
anaesthetised using isoflurane (3% isoflurane/97% oxygen). Anaes-
thesia was maintained using mechanical ventilation (Inspira Venti-
lator) following endotracheal intubation using 130–140 breaths per
minute and 5 ml/kg tidal volume initially, increased to 7.5 ml/kg
post-thoracotomy. Left-side thoracotomy was performed through
the fourth intercostal space and the left anterior descending (LAD)
coronary artery was ligated immediately below the left atria with a
7-0 prolene suture. Successful occlusion of the vessel was verified
by immediate blanching of the left ventricular myocardium (Fig. 1).
Mice in the sham group underwent left-side thoracotomy without
LAD ligation. The chest was closed, mice were extubated and
buprenorphine (Vetergesic, 0.05 mg/kg) was administered subcuta-
neously for post-operative analgesia. Mice were placed in a 33 °C in-
cubator for 2 h immediately post-surgery to facilitate recovery and
given soaked diet for 1 week so they did not have to stretch for
food during the main period of thoracic wound repair.2.2. Cardiac MRI
Magnetic resonance images were acquired at 1 week and 4 weeks
following MI surgery using a horizontal bore 7.0T Varian microimaging
system (Varian Inc., Palo Alto, CA, USA) equipped with a 12-cm
microimaging gradient insert (40 gauss/cm). Animals were
anaesthetised with isoflurane via a facemask and positioned on a
custom built sled (Dazai Research Instruments, Toronto, Canada),
with integrated electrocardiographic (via electrodes fastened to the
shaved chest with conductive hydro-gel), respiratory (via a pneu-
matic pillow) and cutaneous temperature monitoring. An SA Instru-
ments Inc. (Edison, NJ, USA) small animal system was used for
physiological monitoring and gating. A 30 mm quadrature birdcage
coil (Rapid Biomedical, GmbH) was used to transmit/receive the
MR signal. Scout images were used to ensure that the short and
long axes of the left ventricle were correctly orientated. Global cardiac
functionwasmeasured using an ECG triggered, respiratory gated gradi-
ent echo (FLASH) cine MR sequence using the following imaging pa-
rameters: TE 1.36 ms, TR 5 ms, flip angle 15°, matrix 128 × 128, field
of view 25.6 mm× 25.6 mm, and 4 averages. The cardiac cycle was im-
aged across a minimum of 20 phases in all animals. Sufficient contigu-
ous short axis slices of 1 mm thickness were obtained to cover the
whole left ventricle.
2.3. MR image analysis
MR images confirmed expected cardiac changes (Fig. 2) and short
axis imageswere analysed using Image J (NIH) bymanually tracing epi-
cardial and endocardial borders as previously published [8]. The area
between the epicardial and endocardial borders was measured in all
slices at end diastole and end systole to generate myocardial area per
slice. The total myocardial volume (mm3) was calculated as the sum
of myocardial area per slice (mm2) × number of slices × slice thickness
(1mm/slice). LVmass was calculated asmyocardial volume timesmyo-
cardial specific gravity (1.05 mg/mm3) and was presented as the aver-
age of mass independently calculated from end diastolic and end
systolic measurements. Accurate measurement of MRI image analysis
was confirmed in 3ways: (i) nomore than 5% difference in themyocar-
dial mass calculated at end-diastole and end-systole; (ii) MR data was
independently analysed by two investigators on 6 mice at both time
points; and (iii) calculated mass showed good correlation with actual
mass measured at autopsy (r = 0.91). To measure cardiac function,
the LV chamber area outlined by the endocardial border for each slice
at end diastole and end systole was measured and calculated for each
slice at end diastole and end systole as LV volume per slice = LV
area × slice thickness. The LV end-diastolic volume (LV-EDV) =∑ LV
volume per slice at end-diastole; and the LV end-systolic volume
(LV-ESV) =∑ LV volume per slice at end-systole. Functional pa-
rameters were calculated from these volumes as follows:
Stroke volume SVð Þ ¼ LV‐EDV−LV‐ESV μlð Þ:
Ejection fraction EFð Þ %ð Þ ¼ SV=LV‐EDVð Þ  100:
Infarcted tissue is characterised by thinned, akinetic myocardium
and infarct volumewas calculated as a percentage of the left ventricular
myocardium at end-diastole by measuring epicardial and endocardial
infarct length (Iep and Ien) as a proportion of total epicardial and endo-
cardial circumference (Tep and Ten) across all slices as previously de-
scribed [8]. Infarct size (%) = 1/NSLICES Σ 1/2(Iep/Tep + Ien/Ten) × 100.
2.4. Statistics
Multiple regression analyseswere performedusing STATA and R sta-
tistical software. Linear regression and correlationwere calculatedusing
Graphpad Prism 6. Statistical significance was assumed when p b 0.05.
Fig. 1.Mousemodel of myocardial infarction by surgical ligation of the left anterior descending artery (LAD). A:Mouse heart 24 h following the occlusion of the LAD coronary artery. Note
that in life, the left atrium is blood-filled and reaches just above the ligature. The ischaemic myocardium can be seen by the blanched area of myocardium extending to the apex. B: The
position of the LAD coronary artery has been delineated with black lines and the boundary of the ischaemic area by dashed white line. C, D: Transverse sections of normal heart (C) and
infarcted heart (D) taken 4 weeks after surgery and stained with Masson's trichrome to reveal extensive fibrosis (blue) associated with the dilated left ventricle in the infarcted heart.
Abbreviations: LA, left atrium; LV, left ventricle; RV, right ventricle.
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Cine MRI of infarcted heart shows the remodelled and enlarged
LV chamber at 4 weeks post-MI, whilst the infarcted region can be
recognised as a thinned area of akinetic myocardium (Fig. 2) [8].
Our aim was to determine which primary measure of cardiac func-
tion using MRI was best able to predict subsequent adverse out-
comes and could be used as a predictive measure in future studies
of therapeutic interventions. Week 1 was chosen for the baseline
measurements for three reasons. First, some initial remodelling is
needed to provide sufficiently early changes to permit analysis of
therapies targeting further detrimental remodelling in future stud-
ies. Second, MR measurements at 1 week following acute MI have
been shown to have greater predictive value for patient LV function
than MR data at earlier time points [17]. Third, from the animal
ethics (3Rs) perspective, one week allowed good recovery from the
thoracotomy before mice were subject to transfer to the MR suite
and further anaesthesia during the scans. The primary variables mea-
sured at week 1 were LV-EDV, LV-ESV, infarct size and LV-cardiac mass.
Ejection fraction (EF) was also included as a key measure of cardiacfunctional, and represents a secondary variable calculated from LV-
EDV and LV-ESV. The mice were then subjected to a second scan
when the scar tissue had matured at 4 weeks post-MI. At this stage, in-
creased LV-EDV and LV-ESV reflected adverse cardiac remodelling and
chamber enlargement, whilst increased LV cardiacmass reflected cardi-
ac hypertrophy and reduced ejection fraction corresponded to de-
creased cardiac function.
We first examined the relationship between each of five early vari-
ables at week 1 post-MI (LV-EDVwk1, LV-ESVwk1, LV-masswk1, ISwk1
and LV-EFwk1) to each of the outcome measures at 4 weeks (LV-
EDVwk4, LV-ESVwk4, LV-masswk4, and LV-EFwk4) (Table 1). LV-ESVwk1
was highly correlated with LV-ESVwk4 (r = 0.97; p = 1.3 × 10−15),
and LV-ESVwk1 showed the highest correlation with LV-EDVwk4 (r = 0
99; p = 0.0000), a major readout of adverse left ventricular remod-
elling. In addition, LV-ESVwk1 was highly correlated with increased
LV-masswk4 (r = 0.96; p = 9.5 × 10−14). However, LV-ESVwk1 did
not show the highest correlation with LV-EFwk4 (r = −0.64; p =
6.2 × 10−4), and it was LV-EFwk1 that showed the highest correlation
with LV-EFwk4 (r = 0.74; p = 2.5 × 10−5) (Table 1). Linear regres-
sion analysis illustrates these key findings in Fig. 3.
Fig. 2.MRI images of normal and infarctedmouse hearts. A–F:MRI images of short, horizontal and long axis views of a normalmouse heart in systole anddiastole. G–L:MRI images of short,
horizontal and long axis views of an infarctedmouse heart 4weeks after surgical ligation of the LAD.Note the enlarged left ventricle and thinned, akinetic area of the infarctedmyocardium
(arrows in I, J, K & L).
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minewhich of theweek 1 variables could best predict each of the differ-
ent cardiac outcomes atweek 4. Using thismodel, LV-ESV atweek 1was
the strongest predictor variable for increased cardiac volume and mass
measurements atweek 4 (LV-EDV, LV-ESV and LV-cardiacmass) and no
other variable made any significant contribution to the fit of the model.
In contrast, LV-EFwk1 was the best predictor for LV-EFwk4 and inclusion
of further week 1 variables (LV mass, LV-EDV, LV-EF or infarct size)
did not significantly improve the fit to the model. These data confirm
that LV-ESVwk1 is a very useful predictor variable for detrimental cardiac
remodelling outcomes (increased LV-EDV, LV-ESV and LV-cardiac
mass) at one month following infarction. Furthermore, LV-ESVwk1
is the most robust predictor of later adverse cardiac remodelling,Table 1
Correlation of cardiac measurements at one week following myocardial infarction with outcom
Correlation coefficients (r) from univariate analysis (taking each week 1 variable against each w
(LV-ESVwk1) is the best predictor variable for all outputs atweek four except for ejection fraction
outcome measure at week four are shown in bold, and all corresponding p values are in paren
Variable LV mass wk4 LV-ESV wk
LV mass wk1 0.87
(p = 1.8e−8)
0.85
(p = 7.4e
LV-EDV wk1 0.94
(p = 4.7e−12)
0.95
(p = 7.3e
LV-ESV wk1 0.96
(p = 9.5e−14)
0.97
(p = 1.3e
LV-EF wk1 −0.83
(p = 2.5e−7)
−0.87
(p = 1.1e
IS-wk1 0.85
(p = 6.6e−8)
0.83
(p = 3.6eaccounting for 98% of the variability in LV-EDVwk4. Any future interven-
tion able to reduce late adverse remodelling would be expected to sig-
nificantly reduce the slope of the linear regression line described by
the equation: LV-EDVwk4 = 1.33(LV-ESVwk1) + 26 μl3 (Fig. 3A).
4. Discussion
Reported benefits that attenuate LV dilatation and improve heart
function in pre-clinical studies usingmice are rarely translatable in clin-
ical trials [6], an outcome that may partly reflect poor experimental de-
sign of the pre-clinical study. New consortia aim to address this problem
by establishing shared methodologies to improve the translatability of
preclinical studies using mice [6,18]. However, in the vast majority ofe measures at four weeks.
eek 4 outcome individually) show that left ventricular end systolic function at week one
(EFwk4), inwhich case EFwk1 showed the highest correlation. The highest r values for each
theses.
4 LV-EDV wk4 LV-EF wk4
−8)
0.89
(p = 2.7e−9)
−0.54
(p = 5.5e−3)
−13)
0.98
(p = 0.0000)
−0.59
(p = 1.7e−3)
−15)
0.99
(p = 0.0000)
−0.64
(p = 6.2e−4)
−8)
−0.86
(p = 4.6e−8)
0.74
(p = 2.5e−5)
−7)
0.87
(p = 1.9e−8)
−0.55
(p = 4.6e−3)
Fig. 3. Linear regression analysis to evaluate LV-ESV at one week following MI as a predictor variable of adverse cardiac remodelling at four weeks post-MI. A: Linear regression analysis
confirmed the strong linear relationship between LV-ESVwk1 and LV-EDVwk4 (r2 = 0.98; p b 0.0001) which is described by the equation: LV-EDVwk4 = 1.33(LV-ESVwk1) + 26 μl3. Each
closed black circle represents one mouse following infarction and the open square represents the mean of 11 sham operated animals (standard error of the mean is small and fits
within the size of the open square). B, C: LV-ESVwk1 showed a strong linear relationship with both LV-ESVwk4 (r2 = 0.94; p b 0.0001) and LV-masswk4 (r2 = 0.92; p b 0.0001). D: LV-
EFwk4 showed a reasonably good linear association with LV-EFwk1 (r2 = 0.74; p b 0.0001).
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mouse models, the treated group is compared with the control group
andmean outcomes of ejection fraction or scar size or left ventricle vol-
umes are compared using Student's t-test. Frequently only one of these
values is used (possibly selected as the only one showing statistical sig-
nificance), andwithout the full dataset the conclusionsmay bemislead-
ing. Furthermore, the intrinsic variability in infarct size is likely to have a
major impact on these analyses, and reduce the power of the study.
Therefore in order to explore the predictive value of a mouse model of
MI for pre-clinical studies in away that accounts for variability in infarct
size, we used cardiac MRI to evaluate heart remodelling responses in
male mice following permanent ligation of the LAD coronary artery.
We found that LV-ESVwk1 was a highly predictable measure of later ad-
verse cardiac remodelling (LV-EDVwk4), with increased predictability
over other MRI-derived measures of cardiac properties at week 1,
including LV-EDV, heart mass and infarct size. The extent of adverse re-
modelling as judged by EDVwk4 was directly proportional to LV-ESVwk1
with small infarcts increasing by the same proportion as larger infarcts.
This finding is in contrast to a previous study using female mice which
observed a biphasic response,with smaller infarcts showingnoprogres-
sion [9]. This difference could be due to gender differences in the mice
used for the studies. We used only male micewhich showmore inflam-
mation and reduced reparative fibrosis during infarct healing than
females [10–13], and this may explain why even small infarcts still
showed some adverse remodelling in our study. In contrast, the reduced
inflammation in females and increased reparative fibrosis may explain
the lack of progression of small infarcts previously reported [9]. Alterna-
tively, the direct linear regression relationship between early and later
points in our study may be because the initial adverse remodelling
events are better established at the 1 week post-MI time point,
compared with the 2 day time point used by Protti et al. [9]. Although
stepwise forward analysis did not reveal any additional contributionof infarct size at week 1 over LV-ESVwk1 to predict adverse remodelling,
univariate correlation analysis showed that infarct size measured by
simple manual tracing of thinned akinetic myocardium [8] significantly
correlated with LV-EDVwk4 outcomes (r= 0.87; p b 0.0001). Further-
more, laboratories without access to a pre-clinical MRI facility could
potentially use evaluation of end diastolic diameter (EDD) by echo-
cardiography as an alternative predictive measure at early time
points post-MI, although caution is needed because this technique
is open to more subjective interpretation than MRI.
Progressive ventricular dilatation after myocardial infarction is part
of a complex cardiac remodelling process involving changes in mass,
shape and volume [3]. Limited left ventricular dilatation can help to re-
tain cardiac function and is therefore compensatory, but further dilata-
tion can result in severe LV dysfunction and heart failure. Patients with
major LV remodelling have worse prognosis than patients with smaller
changes [2,3] and even small reductions in adverse LV remodelling can
reduce the risk of progression to heart failure [19,20]. Although EF is the
most frequently usedmeasure of heart function based on its clinical im-
portance, it reflects a combination of heart dilatation and myocardial
contractile function, making it more challenging to interpret than the
simpler mathematical measurement of left ventricle enlargement over
time to quantify adverse cardiac remodelling.
4.1. Study limitations
Limitations of using mouse models of clinical MI include the differ-
ent coronary anatomy of mice and humans [21]. LAD ligation in
mouse occludes the vascular supply to much of the free wall of the left
ventricle, sparing the septum and right ventricle. Mice have a distinct
septal coronary artery from the ostium above the right sinus or as a
branch of the right coronary artery, resulting in sparing of the interven-
tricular septum after occlusion of the LAD [21]. In contrast, the vascular
34 R.E. Redgrave et al. / IJC Heart & Vasculature 11 (2016) 29–34network of the interventricular septum in human hearts is frequently
supplied by branches from the LAD which means that myocardial in-
farction due to occlusion of the LAD frequently affects the septal
myocardium. A further limitation is the use of healthy young adult
mice in these types of study, whereas oldermice with atherosclerosis
(e.g. ApoE mutant mice) would provide a more clinically relevant
study population.We also acknowledge that measurement of cardiac
function at 1 week post-MI would not provide a useful baseline for
measuring early cardioprotective treatments, e.g. ischaemic pre-
conditioning where reproducible benefit can be seen in pre-clinical
models at 48 h post-MI [18]. However, it is an ideal time point for
testing therapies designed to reduce progressive adverse remodelling
where patient risk is ascertained byMR followingMI. In the clinical set-
ting, MRmeasurements at 1 week following acute MI have greater pre-
dictive value for patient LV function thanMRdata acquired at day 2 [17].
5. Conclusion
Our findings suggest that MRI evaluation of LV-ESV at one week fol-
lowing MI in mouse models can be used to accurately predict subse-
quent adverse remodelling and therefore represents a reliable baseline
measure to facilitate a more robust analysis of interventions to amelio-
rate adverse progression of cardiac remodelling following MI.
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